Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ONYX long-term extension of apitegromab in type 2 and type 3 spinal muscular atrophy
2024-511654-42-00Phase 3Authorised
- Sponsor
- Scholar Rock
- Start
- Jun 2023
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 9
01
Overview
Phase 3, open-label, single-arm trial of apitegromab in spinal muscular atrophy (SMA), sponsored by Scholar Rock. Primary endpoint: Incidence of treatment-emergent adverse events and serious adverse events by severity. Planned start Jun 2023; status: authorised.
02
Drugs
apitegromab
03
Conditions
spinal muscular atrophy (SMA)
Beyond the preview
Go deeper on 2024-511654-42-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-511654-42-00.